Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-09-19
2008-05-20
Navarro, Mark (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S004000, C435S252300, C435S320100, C435S975000
Reexamination Certificate
active
07375190
ABSTRACT:
This invention provides recombinant protein comprising formula as follows:in-line-formulae description="In-line Formulae" end="lead"?A-Bin-line-formulae description="In-line Formulae" end="tail"?wherein A is polypeptide containing glutamine-rich domain comprising 8-200 glutamine residues and B is color-alteration enzyme modulated by the domain. This invention also provides an expressing vector and a cell produced therefrom. This invention further provides a method and a kit for screening a therapeutic agent for a neurodegenerative disease.
REFERENCES:
Brigit E. Riley et al., “Polyglutamine neurodegenerative diseases and regulation of transcription assembling the puzzle,”Genes&Development, vol. 20, pp. 2183-2192 (2006).
Yoko Kimura et al., “Therapeutic Prospects for the prevention of Neurodegeneration in Huntingdon's Disease and the Polyglutamine Repeat Disorders,”Mini Reviews in Med. Chem., vol. 7, pp. 99-106 (2007).
The Huntington's Disease Collaborative Research Group, “A Novel Gene Containing a Trinucleotide Repeat that is Expanded and Unstable on Huntington's Disease Chromosomes,”Cell, vol. 72, pp. 971-983 (1993).
C.A. Ross, “Polyglutamine Pathogenesis: Emergence of Unifying Mechanisms for Huntingdon's Disease and Related Disorders,”Neuron, vol. 35, pp. 819-822 (2002).
H.Y. Zoghbi et al., “Glutamien Repeats and Neurodegeneration,”Annu. Rev. Neurosci, vol. 23, pp. 217-247 (2000).
S.W. Davies et al., “Formation of Neuronal Intranuclear Inclusion Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation,”Cell, vol. 90, pp. 537-548 (Aug. 8, 1997).
M. DiFiglia et al., “Aggregation of Huntingtin in Neuronal Intranculear Inclusions and Dystrophic Neurites in Brain,”Science, vol. 277 1990-1993 (Sep. 26, 1997).
L. Mangiarini et al., “Exon 1 of theHDGene with an Expanded CAG Repeat is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice,”Cell, vol. 87, pp. 493-506 (Nov. 1, 1996).
P. Hemachandra Reddy et al., “Recent advances in understanding the pathogenesis of Huntington's disease,”TINS, vol. 22, No. 6, pp. 248-255 (1999).
I. Sanchez et al., “Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders,”Letters to Nature, vol. 421, pp. 373-379 (Jan. 23, 2003).
M. Tanaka et al., “Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntingdon's disease,”Nature Medicine, vol. 10, No. 2, pp. 148-154 (Feb. 2004).
C.A. Ross et al., “Polyglutamine fibrillogenesis: The pathway unfolds,”PNAS, vol. 100, No. 1, pp. 1-3 (Jan. 7, 2003).
J. K. Cooper et al., “Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture,”Human Molecular Genetics, vol. 7, No. 5, pp. 783-790 (1998).
Shi-Hua Li et al., “Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats,”Human Molecular Genetics, vol. 7, No. 5, pp. 777-782 (1998).
S. Krobitsch et al., “Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins,”PNAS, vol. 97, No. 4, pp. 1589-1594 (Feb. 15, 2000).
A.B. Meriin et al., “Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1,”J. Cell Biol., vol. 157, No. 6, pp. 997-1005 (2002).
J. Carmichael et al., “Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease,”PNAS, Vo.. 97, No. 17, pp. 9701-9705 (Aug. 15, 2000).
P.J. Muchowski et al., “Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils,”PNAS, vol. 97, No. 14, pp. 7841-7846 (Jul. 5, 2000).
L.Z. Osherovich et al., “Multiple GIn/Asn-Rich Prion Domains Confer Susceptibility to Induction of the Yeast[PSI+] Prion,”Cell, vol. 106, pp. 183-194 (Jul. 27, 2001).
S.R. Collins et al., “Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition,”PLoS Biol., vol. 2, Issue 10, pp. 1582-1590 (Oct. 2004).
I.L. Derkatch et al., “Effects of Q/N-rich, polyQ, and Non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup 35 in vitro,”PNAS, vol. 101, No. 35, pp. 12934-12939 (Aug. 31, 2004).
K.C. Gokhale et al., “Modulation of Prion-dependent Polyglutamine Aggregation and Toxicity by Chaperone Proteins in the Yeast Model,”J. Biol. Chem., vol. 280, No. 24, pp. 22809-22818 (Jun. 17, 2005).
V. Berthelier et al., “A Microtiter Plate Assay for Polyglutamine Aggregate Extension,”Anal. Biochem., vol. 295, pp. 227-236 (2001).
E.E. Wanker et al., “Membrane Filter Assay for Detection of Amyloid-like Polyglutamine-Containing Protein Aggregates,”Methods in Enzymology, vol. 309, pp. 375-386, (1999).
S.K. Pollitt et al., “A Rapid Cellular FRET Assay of Polyglutamine Aggregation Identifies a Novel Inhibitor,”Neuron, vol. 40, pp. 685-694 (Nov. 13, 2003).
X. Zhang et al., “A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo,”PNAS, vol. 102, No. 3, pp. 892-897 (Jan. 18, 2005).
U. Guldener et al., “A new efficient gene disruption cassette for repeated use in budding yeast,”Nucleic Acids Res., vol. 24, No. 13, pp. 2519-2524 (1996).
D. burke et al., “Methods in Yeast Genetics,” Cold Spring Harbor Laboratory Course Manual, App. A, pp. 171-175, 2000 ed.
E. Scherzinger et al., “Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates in vitro and In Vivo,”Cell, vol. 90, pp. 549-558 (Aug. 8, 1997).
Cheng Tzu-Hao
Liu Chia-Rung
Harness & Dickey & Pierce P.L.C.
National Yang-Ming University
Navarro Mark
LandOfFree
Recombinant protein and method of screening for agents that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant protein and method of screening for agents that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant protein and method of screening for agents that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981550